JAMA:VC及VB1对脓毒症休克患者无益

2020-01-21 MedSci MedSci原创

研究认为,氢化可的松治疗基础上添加维生素C和维生素B1不能改善脓毒性休克患者预后

近日研究人员考察了在氢化可的松治疗基础上添加维生素C和维生素B1对脓毒性休克患者的影响。

216名脓毒症休克患者参与,随机分为联合治疗组(n=109),治疗方案为静脉注射VC(每6小时1.5克)、氢化可的松(每6小时50毫克)和VB1(每12小时200毫克)或对照组(n=107,仅接受氢化可的松静脉注射),直到休克缓解。研究的主要终点为存活且未使用加压素时间。

211名患者完成研究,平均年龄61.7岁133名男性。联合治疗组存活且未使用加压素的时间为122.1小时,对照组为124.6小时,无显著性差异。10个预先指定的次要终点中,9个没有统计学差异。联合治疗组90天死亡率为30/105(28.6%),对照组25/102(24.5%,危险比1.18),未发生严重不良事件。

研究认为,氢化可的松治疗基础上添加维生素C和维生素B1不能改善脓毒性休克患者预后。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=900618, encodeId=399090061862, content=就喜欢这种斩钉截铁下结论的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=464e4070825, createdName=898319336, createdTime=Thu Nov 19 21:38:38 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661216, encodeId=0a6116612169a, content=<a href='/topic/show?id=8f80851950a' target=_blank style='color:#2F92EE;'>#脓毒症休克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85195, encryptionId=8f80851950a, topicName=脓毒症休克)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f78125230878, createdName=1249842em17(暂无昵称), createdTime=Mon Oct 05 06:00:00 CST 2020, time=2020-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378387, encodeId=0ad53e838732, content=谢谢了学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Wed Jan 22 00:17:09 CST 2020, time=2020-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035885, encodeId=b33310358855d, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Tue Jan 21 23:00:00 CST 2020, time=2020-01-21, status=1, ipAttribution=)]
    2020-11-19 898319336

    就喜欢这种斩钉截铁下结论的文章

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=900618, encodeId=399090061862, content=就喜欢这种斩钉截铁下结论的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=464e4070825, createdName=898319336, createdTime=Thu Nov 19 21:38:38 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661216, encodeId=0a6116612169a, content=<a href='/topic/show?id=8f80851950a' target=_blank style='color:#2F92EE;'>#脓毒症休克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85195, encryptionId=8f80851950a, topicName=脓毒症休克)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f78125230878, createdName=1249842em17(暂无昵称), createdTime=Mon Oct 05 06:00:00 CST 2020, time=2020-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378387, encodeId=0ad53e838732, content=谢谢了学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Wed Jan 22 00:17:09 CST 2020, time=2020-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035885, encodeId=b33310358855d, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Tue Jan 21 23:00:00 CST 2020, time=2020-01-21, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=900618, encodeId=399090061862, content=就喜欢这种斩钉截铁下结论的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=464e4070825, createdName=898319336, createdTime=Thu Nov 19 21:38:38 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661216, encodeId=0a6116612169a, content=<a href='/topic/show?id=8f80851950a' target=_blank style='color:#2F92EE;'>#脓毒症休克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85195, encryptionId=8f80851950a, topicName=脓毒症休克)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f78125230878, createdName=1249842em17(暂无昵称), createdTime=Mon Oct 05 06:00:00 CST 2020, time=2020-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378387, encodeId=0ad53e838732, content=谢谢了学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Wed Jan 22 00:17:09 CST 2020, time=2020-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035885, encodeId=b33310358855d, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Tue Jan 21 23:00:00 CST 2020, time=2020-01-21, status=1, ipAttribution=)]
    2020-01-22 txqjm

    谢谢了学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=900618, encodeId=399090061862, content=就喜欢这种斩钉截铁下结论的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=464e4070825, createdName=898319336, createdTime=Thu Nov 19 21:38:38 CST 2020, time=2020-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1661216, encodeId=0a6116612169a, content=<a href='/topic/show?id=8f80851950a' target=_blank style='color:#2F92EE;'>#脓毒症休克#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85195, encryptionId=8f80851950a, topicName=脓毒症休克)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f78125230878, createdName=1249842em17(暂无昵称), createdTime=Mon Oct 05 06:00:00 CST 2020, time=2020-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=378387, encodeId=0ad53e838732, content=谢谢了学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Wed Jan 22 00:17:09 CST 2020, time=2020-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035885, encodeId=b33310358855d, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Tue Jan 21 23:00:00 CST 2020, time=2020-01-21, status=1, ipAttribution=)]
    2020-01-21 旺医

    顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息

    0

相关资讯

J Intensive Care:被动抬腿试验:无创监测可以指导脓毒症休克复苏吗?

及时足够的液体复苏是治疗脓毒症休克的基本策略。然而,复苏的先决条件是对液体容积反应性和液体复苏剂量进行评估。初期大量液体复苏及后期液体符合过重都可能会增加疾病死亡率。